This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
clinical cervical-cancer 
European Pharmaceutical Review
MARCH 29, 2023
Pembrolizumab (Keytruda) has been recommended in National Institute for Health and Care Excellence (NICE) final draft guidance for advanced cervical cancer. Clinical trial evidence shows that the treatment helps delay worsening of the disease , compared to standard care.
94 
Pharmaceutical Technology
APRIL 18, 2024
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Cervical Cancer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
DECEMBER 25, 2023
Disitamab vedotin is under clinical development by RemeGen and currently in Phase I for Cervical Cancer.
52 
Pharmaceutical Technology
DECEMBER 22, 2023
Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Cervical Cancer.
52 
Pharmaceutical Technology
DECEMBER 6, 2023
XmAb-662 is under clinical development by Xencor and currently in Phase I for Cervical Cancer.
52 
Pharmacy Times
JANUARY 9, 2024
The accepted sBLA comes after phase 3 clinical trial results which demonstrated better overall survival, progression-free survival, and confirmed overall response rate than chemotherapy in patients with cervical cancer.
48 
World of DTC Marketing
OCTOBER 6, 2020
WHAT’S THIS ABOUT THEN : Researchers are rushing to launch clinical trials of experimental vaccines against the coronavirus, and treatments for COVID-19. We are now seeing impacts on clinical-trial continuity in all the regions where we conduct clinical studies.”.
180 
Pharmaceutical Technology
JANUARY 4, 2024
XTX-101 is under clinical development by Xilio Therapeutics and currently in Phase II for Cervical Cancer.
40 
Pharmaceutical Technology
DECEMBER 20, 2023
VTP-200 is under clinical development by Barinthus Biotherapeutics and currently in Phase II for Cervical Cancer.
40 
Pharmaceutical Technology
NOVEMBER 18, 2023
Tusamitamab ravtansine is under clinical development by Sanofi and currently in Phase II for Cervical Cancer.
40 
Pharmaceutical Technology
NOVEMBER 5, 2023
XB-002 is under clinical development by Exelixis and currently in Phase II for Cervical Cancer.
40 
Pharmaceutical Technology
MARCH 1, 2023
MP-0310 is under clinical development by Molecular Partners and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I drugs for Cervical Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. It is developed based on DARPin technology.
Pharmaceutical Technology
JULY 7, 2023
Oncolytic Virus for Human Papillomavirus Associated Cancer, Human Papillomavirus Infections and Coronavirus Disease 2019 (COVID-19) is under clinical development by Blue Sky Immunotherapies and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN).
40 
Pharmaceutical Technology
JULY 7, 2023
Oncolytic Virus for Human Papillomavirus Associated Cancer, Human Papillomavirus Infections and Coronavirus Disease 2019 (COVID-19) is under clinical development by Blue Sky Immunotherapies and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN).
40 
pharmaphorum
JUNE 27, 2022
Almost half (48%) of cancer clinical trials in the US have no Hispanic or Latin American subjects, and 42% have no black patients, according to a diversity analysis focusing on thousands of studies conducted in the past 15 years. Figure 1: Ethnic composition of cancer clinical trial cohorts in the USA.
106 
Pharmaceutical Technology
FEBRUARY 23, 2023
Buparlisib hydrochloride is under clinical development by Adlai Nortye Biopharma and currently in Phase II for Mantle Cell Lymphoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
52 
European Pharmaceutical Review
JULY 27, 2023
ENHERTU ® (trastuzumab deruxtecan) has demonstrated clinically meaningful progression-free survival (PFS) and overall survival (OS) in topline results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial. These cancers include biliary tract, bladder, cervical, endometrial, ovarian and pancreatic.
86 
Pharmaceutical Technology
FEBRUARY 19, 2023
Danburstotug is under clinical development by Sorrento Therapeutics and currently in Phase III for Cervical Cancer. According to GlobalData, Phase III drugs for Cervical Cancer have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration.
Pharmaceutical Technology
MARCH 23, 2023
Adcetris is currently active in multiple clinical trials, including the ECHELON-3 Phase lll study for patients with relapsed or refractory diffuse large B-cell lymphoma. It is indicated for adults with metastatic cervical cancer as a second-line therapeutic.
59 Pharmaceutical Technology
MAY 31, 2023
ATRN-119 is under clinical development by Aprea Therapeutics and currently in Phase II for Solid Tumor. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It also has pre-clinical research and development to extend its product development.
40 
Pharmaceutical Technology
JUNE 10, 2023
TAS-117 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Chondrosarcoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It was under development for the treatment of gastric cancer and multiple myeloma.
Pharmaceutical Technology
JUNE 10, 2023
TAS-117 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Chondrosarcoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It was under development for the treatment of gastric cancer and multiple myeloma.
PM360
MAY 15, 2023
WHO Moves to Single Dose HPV Vaccine Traditionally done in two or three dose regimens, the human papillomavirus (HPV) vaccine protects against the virus that causes cervical cancer. WHO Assistant Director-General Dr. Princess Nothemba (Nono) Simelela stated, “I firmly believe the elimination of cervical cancer is possible.
52 Pharmaceutical Technology
MARCH 1, 2023
MP-0310 is under clinical development by Molecular Partners and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. The drug candidate is administered through intravenous route.
Pharmaceutical Technology
AUGUST 19, 2022
The European Commission (EC) has granted approval for Celltrion Healthcare ’s Vegzelma (CT-P16) to treat metastatic breast cancer, advanced and/or metastatic renal cell cancer, non-small cell lung cancer, ovarian cancer, metastatic carcinoma of the colon or rectum and cervical cancer.
Pharmaceutical Technology
FEBRUARY 20, 2023
ABN-401 is under clinical development by Abion and currently in Phase II for Solid Tumor. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The drug candidate is a triazolopyrazine derivative. Abion is headquartered in Seoul City, Seoul, South Korea.
Pharmaceutical Technology
FEBRUARY 26, 2023
Cellular Immunotherapy for Non-Small Cell Lung Cancer is under clinical development by Iovance Biotherapeutics and currently in Phase II for Non-Small Cell Lung Cancer. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Buy the report here.
40 
pharmaphorum
DECEMBER 6, 2022
It’s been a torrid few years for Summit, which has seen two lead drug candidates – ezutromid for Duchenne muscular dystrophy and Clostridium difficile infection therapy ridinilazole –fail in mid- to late-stage clinical trials.
52 
Pharmaceutical Technology
MAY 31, 2023
Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III.
Pharmaceutical Technology
FEBRUARY 19, 2023
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Solid Tumor. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
40 Pharmaceutical Technology
JUNE 6, 2023
According to Globaldata, it is involved in 1 clinical trial, which is ongoing. The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. Buy the model here. It is developed based on ZymeLink technology. It is administered through intravenous route.
40 
Pharmaceutical Technology
JUNE 6, 2023
Ecubectedin is a small molecule commercialized by Pharma Mar, with a leading Phase II program in Hormone Sensitive Breast Cancer. According to Globaldata, it is involved in 5 clinical trials, which are ongoing. Pharma Mar Overview Pharma Mar discovers, develops and markets marine-derived drugs to treat cancer.
40 
Clarivate
MAY 11, 2023
One major impediment to faster approvals was stringent registration requirements to conduct domestic trials in order to supplement clinical evidence generated in global trials. CDE also released guidelines on Clinical trial requirements for overseas drugs.
52 
Medgadget
FEBRUARY 28, 2023
The neuromodulation device is intended to be implanted on the left cervical vagus nerve in an outpatient procedure. This strategy can be effective in reducing damage due to inflammation but leads to immunosuppression with risks of severe infections and cancer. It stimulates the nerve with electrical pulses.
95 
pharmaphorum
DECEMBER 19, 2022
Taking a brief look back to pharmaphorum’s coverage of Day One of The Economist’s 8th Annual World Cancer Series congress in Brussels, Belgium, in November – where the foci were “innovation, equity, and excellence”. Other factors, however, include the availability or otherwise of cancer drugs. Crisis and cancer control.
73 
PM360
SEPTEMBER 15, 2022
Disruptions even increased in 2021 for some services such as cancer care and nutrition. Preventive cancer screenings are a good example. Cancer Centers and Organizations Endorse Goal of Resuming Cancer Screening and Treatment During the COVID-19 Pandemic.” 6 Many months later, in January 2021, major U.S. Who’s Affected?
59 
Pharmaceutical Technology
SEPTEMBER 14, 2022
This week, at the European Society of Medical Oncology (ESMO) Congress 2022 researchers presented encouraging updates on immunotherapies in the field of cervical cancer. September marks Gynaecological Cancer awareness month, and cervical cancer ranks as the fourth most prevalent cancer for women worldwide.
European Pharmaceutical Review
NOVEMBER 24, 2022
s Libtayo ® (cemiplimab) for adults with recurrent or metastatic cervical cancer and disease progression while on or after platinum-based chemotherapy. Clinical trial for metastatic cervical cancer. Libtayo ® clinical trial safety data. to 0.84; p=0.00011). months Libtayo ® , 8.8 to 0.91; p=0.00306).
89 
Celeritas
NOVEMBER 21, 2022
Findings show that AuNPs have been pivotal in the reduction of systemic drug toxicity and have lowered the development of resistance to cancer drugs [8]. The unique electromagnetic properties of carbon nanotubes (CNTs) have made them highly valuable in the transport of oligonucleotides into living Hela (immortal cervical cancer) cells.
52 
pharmaphorum
NOVEMBER 23, 2022
Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab) as a monotherapy for the treatment of adult patients with second-line recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. The results were published in the New England Journal of Medicine.
59 
Pharmaceutical Technology
NOVEMBER 23, 2022
The European Commission (EC) has granted approval for Regeneron Pharmaceuticals ’ immunotherapy,Libtayo (cemiplimab), as a single agent to treat recurrent or metastatic cervical cancer in adults. It attaches to PD-1 to hinder cancer cells from utilising the PD-1 pathway for suppressing the activation of T-cells.
Pharmaceutical Technology
SEPTEMBER 28, 2022
Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted four new approvals for Merck ’s (MSD outside North America) humanised monoclonal antibody, Keytruda (pembrolizumab), to treat various types of cancers. Cervical cancer and melanoma indication are based on results from the KEYNOTE-826 and KEYNOTE-716 trials, respectively.
59 
Pharmaceutical Technology
MAY 16, 2023
The approval also includes clearance for a Phase I clinical trial protocol of NXP900. Nuvectis now has two precision oncology, clinical-stage drug candidates, each with several potential opportunities in cancers that represent serious conditions of unmet medical need. “We
Medgadget
AUGUST 4, 2023
Conn Hastings, Medgadget: Please give us an overview of uterine cancer, and its current prognosis and prevalence. Allison London Brown, LUMINELLE: The latest data states that we have a growing prevalence of uterine cancer and other uterine disorders. Medgadget: How are such cancers detected and diagnosed at present?
93
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content